There are currently three Clinical Research Nurse FTEs supported by Protocol-Specific Research Support. These nurses support NIH funded PI Initiated clinical research programs conducting high volume, and complex, translational early phase clinical research: Neuro-oncology, BMT, Experimental Therapeutics, GYN Oncology, Radiation Oncology, GU Oncology, Thoracic Oncology and Breast and Ovarian Cancer. All of the studies which qualify for support are reviewed and discussed at the DCCC Executive Committee. After receiving PRMS approval, and review by the Director of the Clinical Trial Shared Resource, the level of support for each trial is assigned. This support Is usually distributed to the programs pursuing pilot and Phase I studies for which external funding does not exist or is inadequate. Decisions are also influenced by innovation, feasibility, and priority of the project. These funds support Individual clinical research nurses and data managers providing salary support by percent effort. As investigative programs acquire external funding support or as new needs develop for clinical investigators, the funding for these positions Is redistributed. The process for awarding this supports starts with the Scientific Priority Score assigned by the Cancer Protocol Committee at initial review. This score is conveyed to the Disease Site Program Director and Principal Investigator as well as the Clinical Trials Office. The Director of the Clinical Trials Office then meets with the PI of the project to discuss the support needed and guidelines for the use of any supplied support (i.e. support must be used for a research nurse or data manager). All studies which qualify for support are discussed and voted on at the DCCC Executive Committee. Decisions are based by priority score, innovation, feasibility, other possible resources for support, duration and patient accrual. All projects are early pilot or Initial phase testing of an agent or device for the diagnosis, prevention, detection or treatment of cancer. All of these clinical trials are reviewed for scientific progress at the time of full audit and through the annual scientific reviews by the Scientific Monitoring Subcommittee. This group is also charged with closing studies which do not meet accrual goals within appropriate time metrics. The Clinical Trials Protocol Office monitors the effort of staff receiving support through this Shared Resource and reports to the Director of the Clinical Trials Shared Resource and the Director of the DCCC on this status quarterly. Duke University School of Medicine and Health System has and continues to make a significant commitment to oncology clinical research. Duke supports clinical trials review, independent monitoring and safety desk. Oncology will play a key role in Duke's future plans. Including the building of a cancer treatment building and recruitment of new faculty. In addition, with the centralization of services through the clinical trials office the disease site program leaders will have funding to mentor and support PI initiated clinical trials, especially for new investigators. The DCCC Clinical Trials Office, with the guidance of the Director of the DCCC and the Director of the Clinic Trials Shared Resource, has put in place mechanisms to provide quality assurance that the funds are appropriately dispersed and utilized. Given these events, especially Duke's commitment to support oncology clinical trials, we feel there will be a significant Increase In the number of PI Initiated innovative clinical trials. As these trials would greatly benefit from nursing and data management support and we are requesting one additional FTE to facilitate the operation and conduct of these trials.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014236-38
Application #
8379576
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-01-01
Budget End
2012-12-31
Support Year
38
Fiscal Year
2012
Total Cost
$145,020
Indirect Cost
Name
Duke University
Department
Type
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Galaz-Montoya, Monica; Wright, Sara J; Rodriguez, Gustavo J et al. (2017) ?2-Adrenergic receptor activation mobilizes intracellular calcium via a non-canonical cAMP-independent signaling pathway. J Biol Chem 292:9967-9974
Lanier, Megan L; Park, Hyeri; Mukherjee, Paramita et al. (2017) Formal Synthesis of (+)-Laurencin by Gold(I)-Catalyzed Intramolecular Dehydrative Alkoxylation. Chemistry 23:7180-7184
Shi, Qiong; Liu, Hongliang; Han, Peng et al. (2017) Genetic Variants in WNT2B and BTRC Predict Melanoma Survival. J Invest Dermatol 137:1749-1756
Woyach, Jennifer A; Ruppert, Amy S; Guinn, Daphne et al. (2017) BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia. J Clin Oncol 35:1437-1443
Wang, Yanru; Freedman, Jennifer A; Liu, Hongliang et al. (2017) Associations between RNA splicing regulatory variants of stemness-related genes and racial disparities in susceptibility to prostate cancer. Int J Cancer 141:731-743
Fayanju, Oluwadamilola M; Hall, Carolyn S; Bauldry, Jessica Bowman et al. (2017) Body mass index mediates the prognostic significance of circulating tumor cells in inflammatory breast cancer. Am J Surg 214:666-671
Leu, David; Spasojevic, Ivan; Nguyen, Huy et al. (2017) CNS bioavailability and radiation protection of normal hippocampal neurogenesis by a lipophilic Mn porphyrin-based superoxide dismutase mimic, MnTnBuOE-2-PyP5. Redox Biol 12:864-871
Sauer, Scott J; Tarpley, Michael; Shah, Imran et al. (2017) Bisphenol A activates EGFR and ERK promoting proliferation, tumor spheroid formation and resistance to EGFR pathway inhibition in estrogen receptor-negative inflammatory breast cancer cells. Carcinogenesis 38:252-260
Pan, Yongchu; Liu, Hongliang; Wang, Yanru et al. (2017) Associations between genetic variants in mRNA splicing-related genes and risk of lung cancer: a pathway-based analysis from published GWASs. Sci Rep 7:44634
Yin, Jieyun; Liu, Hongliang; Liu, Zhensheng et al. (2017) Pathway-analysis of published genome-wide association studies of lung cancer: A potential role for the CYP4F3 locus. Mol Carcinog 56:1663-1672

Showing the most recent 10 out of 480 publications